Serogroup B and C serum bactericidal assays

Area of Science:

• Bacteriology
• Immunology
• Vaccinology

Background:

• Meningococci are classified by polysaccharide capsule serogroups (A, B, C), with B and C predominating in the Americas and Europe.
• Serogroup A meningococci cause widespread outbreaks in the African meningitis belt.
• Licensed vaccines exist for serogroups A and C, but not for serogroup B due to poor human immunogenicity.

Purpose of the Study:

• To detail serum bactericidal assay protocols for measuring complement-mediated lysis of serogroup B and C meningococci.
• To provide methods for assessing immune responses following vaccination or disease.
• To support the development of vaccines against meningococcal disease.

Main Methods:

• Serum bactericidal assays (SBAs) using human sera.
• Measurement of complement-mediated bacterial lysis.
• Protocols for serogroups B and C meningococci.

Main Results:

• Established protocols for serum bactericidal assays against meningococcal serogroups B and C.
• Demonstrated the utility of SBAs in evaluating immune responses to meningococcal antigens.
• Provided a framework for vaccine immunogenicity studies.

Conclusions:

• Serum bactericidal assays are essential for evaluating the efficacy of vaccines against meningococcal serogroups B and C.
• Standardized protocols are critical for reproducible assessment of vaccine-induced immunity.
• Further development of serogroup B vaccines is needed, and these assays will be vital for their evaluation.